89 related articles for article (PubMed ID: 22094098)
1. [Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells].
Jiang XJ; Meng FY; Huang KK; Zhou HS; Wang Q
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(32):2287-92. PubMed ID: 22094098
[TBL] [Abstract][Full Text] [Related]
2. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
[TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Ramakrishnan V; Kimlinger T; Timm M; Haug J; Rajkumar SV; Kumar S
Leuk Res; 2014 Nov; 38(11):1358-66. PubMed ID: 25282334
[TBL] [Abstract][Full Text] [Related]
4. RAD001 can reverse drug resistance of SGC7901/DDP cells.
Ying L; Zu-An Z; Qing-Hua L; Qing-Yan K; Lei L; Tao C; Yong-Ping W
Tumour Biol; 2014 Sep; 35(9):9171-7. PubMed ID: 24920069
[TBL] [Abstract][Full Text] [Related]
5. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
7. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
Lemoine M; Derenzini E; Buglio D; Medeiros LJ; Davis RE; Zhang J; Ji Y; Younes A
Blood; 2012 Apr; 119(17):4017-25. PubMed ID: 22408261
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
9. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
10. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effect of Baicalin and Adriamycin in Resistant HL-60/ADM Leukaemia Cells.
Zheng J; Asakawa T; Chen Y; Zheng Z; Chen B; Lin M; Liu T; Hu J
Cell Physiol Biochem; 2017; 43(1):419-430. PubMed ID: 28869936
[TBL] [Abstract][Full Text] [Related]
12. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
[TBL] [Abstract][Full Text] [Related]
13. [Effect and Mechanism of Atorvastatin on Reversing Drug Resistance in Leukemia by Regulating Glycolysis through PTEN/mTOR Pathway].
Liu M; Zhou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):38-44. PubMed ID: 36765474
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of Apoptosis for Resveratrol-mediated Reversing the Drug-resistance of AML HL-60/ADR cells].
Guo YK; Shi M; Qin YL; Li YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):736-742. PubMed ID: 28641627
[TBL] [Abstract][Full Text] [Related]
15. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
16. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
[TBL] [Abstract][Full Text] [Related]
17. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
18. RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5.
Lee MW; Kim DS; Eom JE; Ko YJ; Sung KW; Koo HH; Yoo KH
Biochem Biophys Res Commun; 2015 Aug; 463(4):894-9. PubMed ID: 26074143
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
[TBL] [Abstract][Full Text] [Related]
20. [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang R; Li X; Huang X; Yang X; Li W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 34(6):515-22. PubMed ID: 19587434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]